The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00209805%3A_____%2F16%3AN0000059" target="_blank" >RIV/00209805:_____/16:N0000059 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216224:14110/16:00093104

Výsledek na webu

<a href="http://www.biomed.cas.cz/physiolres/pdf/65/65_S455.pdf" target="_blank" >http://www.biomed.cas.cz/physiolres/pdf/65/65_S455.pdf</a>

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors

Popis výsledku v původním jazyce

Monoclonal antibody-based treatment of cancer has been established as one of the most successful therapeutic strategies for both hematologic malignancies and solid tumors. In addition to targeting cancer antigens antibodies can also modulace immunological pathways that are critical to immune surveillance. Antibody therapy directed against several negative immunologic regulators (checkpoints) is demonstrating significant success in the past few years. Immune checkpoint inhibitors, ipilimumab, pembrolizumab and nivolumab, have shown significant clinical benefit in several malignancies and are already approved for advanced melanoma and squamous NSCLC. Based on thein mechanism of action, these agents can exert toxicities that are unlike conventional cytotoxic chemotherapy, whose nature is close to autoimmune diseases - immune related adverse events (irAEs). In this review we focus on the spectrum of irAEs associated with immune checkpoint antibodies, discussing the pharmacological treatment strategy and possible clinical impact.

Název v anglickém jazyce

The safety of therapeutic monoclonal antibodies: implications for cancer therapy including immuno-checkpoint inhibitors

Popis výsledku anglicky

Monoclonal antibody-based treatment of cancer has been established as one of the most successful therapeutic strategies for both hematologic malignancies and solid tumors. In addition to targeting cancer antigens antibodies can also modulace immunological pathways that are critical to immune surveillance. Antibody therapy directed against several negative immunologic regulators (checkpoints) is demonstrating significant success in the past few years. Immune checkpoint inhibitors, ipilimumab, pembrolizumab and nivolumab, have shown significant clinical benefit in several malignancies and are already approved for advanced melanoma and squamous NSCLC. Based on thein mechanism of action, these agents can exert toxicities that are unlike conventional cytotoxic chemotherapy, whose nature is close to autoimmune diseases - immune related adverse events (irAEs). In this review we focus on the spectrum of irAEs associated with immune checkpoint antibodies, discussing the pharmacological treatment strategy and possible clinical impact.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

<a href="/cs/project/LM2015090" target="_blank" >LM2015090: Český národní uzel Evropské sítě infrastruktur klinického výzkumu</a><br>

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Physiological Research

ISSN

0862-8408

e-ISSN

—

Svazek periodika

65

Číslo periodika v rámci svazku

Suppl4

Stát vydavatele periodika

CZ - Česká republika

Počet stran výsledku

8

Strana od-do

S455-S462

Kód UT WoS článku

000392029200005

EID výsledku v databázi Scopus

—